Literature DB >> 10189540

Intact proinsulin and beta-cell function in lean and obese subjects with and without type 2 diabetes.

M E Røder1, B Dinesen, S G Hartling, P Houssa, H Vestergaard, F Sodoyez-Goffaux, C Binder.   

Abstract

OBJECTIVE: Type 2 diabetes is a heterogeneous disease in which both beta-cell dysfunction and insulin resistance are pathogenetic factors. Disproportionate hyperproinsulinemia (elevated proinsulin/insulin) is another abnormality in type 2 diabetes whose mechanism is unknown. Increased demand due to obesity and/or insulin resistance may result in secretion of immature beta-cell granules with a higher content of intact proinsulin. RESEARCH DESIGN AND METHODS: We investigated the impact of obesity on beta-cell secretion in normal subjects and in type 2 diabetic patients by measuring intact proinsulin, total proinsulin immunoreactivity (PIM), intact insulin, and C-peptide (by radioimmunoassay) by specific enzyme-linked immunosorbent assays in the fasting state and during a 120-min glucagon (1 mg i.v.) stimulation test. Lean (BMI 23.5 +/- 0.3 kg/m2) (LD) and obese (30.1 +/- 0.4 kg/m2) (OD) type 2 diabetic patients matched for fasting glucose (10.2 +/- 0.6 vs. 10.3 +/- 0.4 mmol/l) were compared with age- and BMI-matched lean (22.4 +/- 0.6 kg/m2) (LC) and obese (30.8 +/- 0.9 kg/m2) (OC) normal control subjects.
RESULTS: Diabetic patients (LD vs. LC and OD vs. OC) had elevated fasting levels of intact proinsulin 6.6 +/- 1.0 vs. 1.6 +/- 0.3 pmol/l and 7.7 +/- 2.0 vs. 1.2 +/- 0.2 pmol/l; PIM: 19.9 +/- 2.5 vs. 5.4 +/- 1.0 pmol/l and 29.6 +/- 6.1 vs. 6.1 +/- 0.9 pmol/l; and total PIM/intact insulin: 39 +/- 4 vs. 15 +/- 2% and 35 +/- 5 vs. 13 +/- 2%, all P < 0.01. After glucagon stimulation, PIM levels were disproportionately elevated (PIM/intact insulin based on area under the curve analysis) in diabetic patients (LD vs. LC and OD vs. OC): 32.6 +/- 6.7 vs. 9.2 +/- 1.1% and 22.7 +/- 5.2 vs. 9.1 +/- 1.1%, both P < 0.05. Intact insulin and C-peptide net responses were significantly reduced in type 2 diabetic patients, most pronounced in the lean group. The ratio of intact proinsulin to PIM was higher in diabetic patients after stimulation in both LD versus LC: 32 +/- 3 vs. 23 +/- 2%, and OD versus OC: 28 +/- 4 vs. 16 +/- 2%, both P < 0.01. In obese normal subjects, intact proinsulin/PIM was lower both in the fasting state and after glucagon stimulation: OC versus LC: 22 +/- 3 vs. 33 +/- 3% (fasting) and 16 +/- 2 vs. 23 +/- 2% (stimulated), both P < 0.05.
CONCLUSIONS: Increased secretory demand from obesity-associated insulin resistance cannot explain elevated intact proinsulin and disproportionate hyperproinsulinemia in type 2 diabetes. This abnormality may be an integrated part of pancreatic beta-cell dysfunction in this disease.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10189540     DOI: 10.2337/diacare.22.4.609

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   19.112


  16 in total

1.  Different β-cell secretory phenotype in non-obese compared to obese early type 2 diabetes.

Authors:  Lalitha Gudipaty; Nora K Rosenfeld; Carissa S Fuller; Marina Cuchel; Michael R Rickels
Journal:  Diabetes Metab Res Rev       Date:  2020-02-17       Impact factor: 4.876

Review 2.  Ipragliflozin: A novel sodium-glucose cotransporter 2 inhibitor developed in Japan.

Authors:  Tsuyoshi Ohkura
Journal:  World J Diabetes       Date:  2015-02-15

3.  Influence of BMI, Age and duration of diabetes mellitus on glycaemic control with twice-daily injections of biphasic insulin aspart 30 versus multiple daily injections of insulin aspart (JDDM 18): retrospective reanalysis of a 6-month, randomized, open-label, multicentre trial in Japan.

Authors:  K Arai; K Hirao; M Yamauchi; H Takagi; M Kobayashi
Journal:  Clin Drug Investig       Date:  2010       Impact factor: 2.859

4.  Exercise training and metformin, but not exercise training alone, decreases insulin production and increases insulin clearance in adults with prediabetes.

Authors:  Richard Viskochil; Steven K Malin; Jennifer M Blankenship; Barry Braun
Journal:  J Appl Physiol (1985)       Date:  2017-05-04

5.  Youth type 2 diabetes: insulin resistance, beta-cell failure, or both?

Authors:  Neslihan Gungor; Fida Bacha; Rola Saad; Janine Janosky; Silva Arslanian
Journal:  Diabetes Care       Date:  2005-03       Impact factor: 19.112

6.  In type 2 diabetes patients, insulin glargine is associated with lower postprandial release of intact proinsulin compared with sulfonylurea treatment.

Authors:  Stefan Pscherer; Martin Larbig; Berndt von Stritsky; Andreas Pfützner; Thomas Forst
Journal:  J Diabetes Sci Technol       Date:  2012-05-01

7.  eIF4G1 and carboxypeptidase E axis dysregulation in O-GlcNAc transferase-deficient pancreatic β-cells contributes to hyperproinsulinemia in mice.

Authors:  Seokwon Jo; Amber Lockridge; Emilyn U Alejandro
Journal:  J Biol Chem       Date:  2019-07-12       Impact factor: 5.157

8.  Proinsulin and acute insulin response independently predict Type 2 diabetes mellitus in men--report from 27 years of follow-up study.

Authors:  B Zethelius; L Byberg; C N Hales; H Lithell; C Berne
Journal:  Diabetologia       Date:  2003-01-08       Impact factor: 10.122

9.  Acute and long-term disruption of glycometabolic control after SARS-CoV-2 infection.

Authors:  Laura Montefusco; Moufida Ben Nasr; Francesca D'Addio; Cristian Loretelli; Antonio Rossi; Ida Pastore; Giuseppe Daniele; Ahmed Abdelsalam; Anna Maestroni; Marco Dell'Acqua; Elio Ippolito; Emma Assi; Vera Usuelli; Andy Joe Seelam; Roberta Maria Fiorina; Enrica Chebat; Paola Morpurgo; Maria Elena Lunati; Andrea Mario Bolla; Giovanna Finzi; Reza Abdi; Joseph V Bonventre; Stefano Rusconi; Agostino Riva; Domenico Corradi; Pierachille Santus; Manuela Nebuloni; Franco Folli; Gian Vincenzo Zuccotti; Massimo Galli; Paolo Fiorina
Journal:  Nat Metab       Date:  2021-05-25

10.  Impaired beta cell function is present in nondiabetic rheumatoid arthritis patients.

Authors:  Iván Ferraz-Amaro; Jose A García-Dopico; Lilian Medina-Vega; Miguel A González-Gay; Federico Díaz-González
Journal:  Arthritis Res Ther       Date:  2013-01-22       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.